New Animal Studies Show Potential of Plasma Expander to Treat Combat Casualties; Findings Presented by BioTime, Inc. at APS Annual Meeting.Business Editors and Health/Medical Writers BIOWIRE2K BERKELEY, Calif.--(BW HealthWire)--April 24, 2002 BioTime, Inc. (AMEX AMEX See: American Stock Exchange :BTX (Balanced Technology EXtended) A motherboard design from Intel introduced in 2004 that supersedes the ATX. Unlike the ATX, the placement of all chip sockets in the BTX is defined in order to provide sufficient air flow over the processor and display adapter. ), a company engaged in the research and development of plasma expanders, announced today that new animal studies show the potential of these surgical fluids to reduce the immediate need for blood transfusions in treating combat casualties. The studies were presented yesterday at the annual meeting of the American Physiological Society (APS) in New Orleans, Louisiana. "An Animal Model for Eliminating Battlefield Transfusions" was presented by Dr. Paul Segall, BioTime's Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , as well as Dr. Hal Sternberg, Vice President of Research, and BioTime scientists Mark Voelker, Ph.D. and Stephen Kehrer. More than 14,000 were in attendance at the Annual Meeting of APS, one of the world's most prestigious organizations for physiological scientists. The need for blood transfusions on the battlefield presents a number of logistical problems. Plasma expanders are currently carried and used in combat by certain military personnel, and can act to keep the wounded alive, pressures up, and vital signs stable - until other measures can be administered. "The fact that BioTime's scientific findings were featured at this prestigious conference validates the important role that plasma expanders can play in resuscitation resuscitation /re·sus·ci·ta·tion/ (-sus?i-ta´shun) restoration to life of one apparently dead. cardiopulmonary resuscitation and surgery," said Segall. "We hope our research will help save lives on the battlefield." About BioTime BioTime, headquartered in Berkeley, California develops blood plasma blood plasma n. The yellow or gray-yellow, protein-containing fluid portion of blood in which the blood cells and platelets are normally suspended. volume expanders, blood replacement solutions for hypothermic hy·po·ther·mi·a n. Abnormally low body temperature. [hypo- + Greek therm (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications. Information about BioTime can be found on the web at www.biotimeinc.com. The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the results of clinical trials of BioTime products; BioTime's ability to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and foreign regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime's products; BioTime's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in BioTime products; and the availability of reimbursement for the cost of BioTime products (and related treatment) from government health administration authorities, private health coverage insurers and other organizations. These and other risk factors are discussed in BioTime's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion